A new California startup, Ridge Biotherapeutics, has successfully raised $25 million in seed funding to advance the development of antibody-drug conjugates (ADCs) and other biologics. This significant financial backing comes from notable scientific investors and positions the company to play a pivotal role in the biopharmaceutical landscape.
The funding will enable Ridge Biotherapeutics to leverage innovative technologies and methodologies aimed at improving the efficacy and safety profiles of ADCs. As the demand for more effective targeted therapies continues to rise, especially in oncology, the implications of Ridge’s advancements could be substantial for drug manufacturers seeking to enhance their product portfolios.
With this capital infusion, Ridge Biotherapeutics is poised to accelerate its research and development efforts, potentially reshaping the ADC market and providing biopharma companies with the tools needed to overcome existing challenges in drug development.
